This 2015 randomized, evaluator-blinded, placebo-controlled trial assessed the efficacy of autologous platelet-rich plasma (PRP) injections in treating male pattern hair loss. In a half-head design, 23 patients received PRP on one side of the scalp and placebo on the other, with three treatments administered at 30-day intervals. Results demonstrated a
This 2021 retrospective study examined the use of low-dose oral minoxidil (LDOM) in a North American cohort over a 3-year period to treat various types of alopecia, including androgenetic alopecia and chronic telogen effluvium. The study involved both men and women and found LDOM to be effective in promoting hair
This 2014 review by Avci et al. analyzed the efficacy of low-level laser therapy (LLLT) for treating hair loss, including androgenetic alopecia and alopecia areata. The review encompassed preclinical and clinical studies, showing that LLLT can stimulate hair regrowth in both animal models (e.g., chemotherapy-induced alopecia in mice) and humans.
This 2018 systematic review and network meta-analysis evaluated the comparative effectiveness of six non-surgical treatments for androgenetic alopecia (AGA): dutasteride 0.5 mg, finasteride 1 mg, low-level laser therapy (LLLT), minoxidil 2%, minoxidil 5%, and platelet-rich plasma (PRP). The review included 78 studies, with 22 qualifying for quantitative synthesis. LLLT demonstrated
Finasteride, a 5α-reductase inhibitor, is approved for treating male pattern baldness (androgenetic alopecia) and works by reducing levels of dihydrotestosterone (DHT), a hormone linked to hair loss. Taken orally at 1 mg/day, it significantly improves hair growth and density by preventing the miniaturization of hair follicles. While generally well-tolerated, the
This randomized controlled trial investigated the efficacy of finasteride 1 mg/day in men aged 18 to 41 with androgenetic alopecia over two years. Results showed significant increases in scalp hair counts—107 hairs at 1 year and 138 at 2 years (P < .001)—compared to baseline, while the placebo group experienced
This randomized controlled trial evaluated the efficacy of finasteride 1 mg daily over 24 months in men aged 18 to 60 years with vertex pattern male pattern hair loss. Standardized global photographic assessments showed significant hair regrowth in all scalp regions for younger men (18–41 years), and in the vertex
This systematic review explores the multifaceted causes and treatments of androgenetic alopecia (AGA), emphasizing the importance of early and continuous therapy. It highlights the FDA-approved treatments—topical minoxidil and oral finasteride—while discussing additional therapeutic options targeting androgen activity, inflammation, prostaglandins, and genetic predisposition. The review encourages a personalized, combination-based approach for
This randomized controlled trial compared dutasteride (0.5 mg) and finasteride (1 mg) in men aged 18–40 with androgenetic alopecia (AGA) over 24 weeks. Dutasteride showed significantly superior results in increasing hair count and reducing hair miniaturization compared to finasteride, with similar safety profiles. Both medications had mild to moderate adverse
This randomized, double-blind, placebo-controlled trial published in the International Journal of Dermatology (1993, PMID: 8225725) evaluated the safety and effectiveness of 2% topical minoxidil in 256 women aged 18 to 45 with androgenetic alopecia. Over 32 weeks, participants applied 1 mL of solution twice daily. Results showed a statistically significant
